Please use this identifier to cite or link to this item: http://dspace.lamu.edu.zm:8080/handle/123456789/2871
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMwanza, Sydney-
dc.contributor.authorJoshi, Sudhaunshu-
dc.contributor.authorNambozi, Michael-
dc.contributor.authorChileshe, Justin-
dc.contributor.authorMalunga, Phidelis-
dc.contributor.authorKabuya, Jean‑Bertin Bukasa-
dc.contributor.authorHachizovu, Sebastian-
dc.contributor.authorManyando, Christine-
dc.contributor.authorMulenga, Modest-
dc.contributor.authorLaufer, Miriam-
dc.date.accessioned2023-01-11T07:33:35Z-
dc.date.available2023-01-11T07:33:35Z-
dc.date.issued2016-12-
dc.identifier.citationMwanza, S., Joshi, S., Nambozi, M. et al. The return of chloroquine-susceptible Plasmodium falciparum malaria in Zambia. Malar J 15, 584 (2016). https://doi.org/10.1186/s12936-016-1637-3en_US
dc.identifier.urihttps://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1637-3#citeas-
dc.identifier.urihttp://155.0.177.102:8080/jspui//xmlui/handle/123456789/2871-
dc.descriptionThis journal article can be found at this cite:https://malariajournal.biomedcentral.com/articles/10.1186/s12936-016-1637-3en_US
dc.description.abstractPlasmodium falciparum resistance to anti-malarial drugs remains a major obstacle to malaria control and elimination. The parasite has developed resistance to every anti-malarial drug introduced for wide-scale treatment. However, the spread of resistance may be reversible. Malawi was the first country to discontinue chloroquine use due to widespread resistance. Within a decade of the removal of drug pressure, the molecular marker of chloroquine-resistant malaria had disappeared and the drug was shown to have excellent clinical efficacy. Many countries have observed decreases in the prevalence of chloroquine resistance with the discontinuation of chloroquine use. In Zambia, chloroquine was used as first-line treatment for uncomplicated malaria until treatment failures led the Ministry of Health to replace it with artemether-lumefantrine in 2003. Specimens from a recent study were analysed to evaluate prevalence of chloroquine-resistant malaria in Nchelenge district a decade after chloroquine use was discontinued.en_US
dc.description.sponsorshipThe clinical trial was supported by the European and Developing Countries Clinical Trials Partnership, the Malaria in Pregnancy Consortium (which is funded through a grant from the Bill and Melinda Gates Foundation to the Liverpool School of Tropical Medicine), the Belgian Development Coopera‑ tion Agency, the Liverpool School of Tropical Medicine, the Medical Research Council UK, the Netherlands Organization for Scientific Research, and Sanofi-Aventis. The molecular analysis was supported by K24AI114996 and U01AI087624 to MKL. Ten_US
dc.language.isoenen_US
dc.publisherCross Marken_US
dc.relation.ispartofseriesMalaria Journal;584 (2016)-
dc.subjectPyrosequencingen_US
dc.subjectZambiaen_US
dc.subjectMalariaen_US
dc.subjectPlasmodium falciparumen_US
dc.subjectAnti-malarial resistanceen_US
dc.subjectChloroquineen_US
dc.subjectPfCRTen_US
dc.titleThe return of chloroquine-susceptible Plasmodium falciparum malaria in Zambiaen_US
dc.typeArticleen_US
Appears in Collections:Internal Medicine

Files in This Item:
File Description SizeFormat 
s12936-016-1637-3.pdfModest Mulenga chloroquine937.1 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.